Molecular Partners AG (XSWX:MOLN) 3-Year FCF Growth Rate : -14.10% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG 3-Year FCF Growth Rate?

Molecular Partners AG's Free Cash Flow per Share for the three months ended in Dec. 2023 was CHF-0.50.

During the past 12 months, Molecular Partners AG's average Free Cash Flow per Share Growth Rate was -151.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 11 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Molecular Partners AG was 56.90% per year. The lowest was -35.70% per year. And the median was -13.70% per year.

Competitive Comparison of Molecular Partners AG's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Molecular Partners AG's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's 3-Year FCF Growth Rate falls into.

Molecular Partners AG 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Molecular Partners AG (XSWX:MOLN) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Molecular Partners AG 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.